TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03963570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Step - digital exercise program
Description: After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
Study: NCT05134064

Intervention type: DEVICE
Intervention: total-body PET/CT
Description: PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.
Study: NCT02612480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: 7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
Study: NCT01636856

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal exercises
Description: Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Respiratory exercises, nasal dilator, nasal lavage
Description: Respiratory exercises, nasal dilator, nasal lavage
Study: NCT04595136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug COVID19-0001-USR
Description: COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.9% NS via nebulization
Study: NCT01346423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary intervention
Description: Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group, Brief Intervention
Description: The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
Study: NCT02140450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: 2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
Study: NCT02612480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid lysinate
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid lysinate
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid lysinate
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 day treatment with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 day treatment with placebo
Study: NCT02789384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices.
Study: NCT02560662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call.
Study: NCT05058209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide extended-release injectable suspension
Description: Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Description: Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.
Study: NCT02309112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A mind-body therapy that includes specified breathing, meditation and physical postures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A mind-body therapy that includes specified breathing, meditation and physical postures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A mind-body therapy that includes specified breathing, meditation and physical postures.
Study: NCT04501861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Vasopressin (20 IU/100 ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
Study: NCT03767725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
Study: NCT02530814

Intervention type: OTHER
Intervention: Blood Collection
Description: Onetime blood collection.
Study: NCT00314067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physician training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physician training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Practice team training
Study: NCT02723058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICMHM
Description: ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
Study: NCT04449848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sitting after intra tympanic injection
Description: Sitting after intra tympanic injection
Study: NCT03837808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
Study: NCT03522805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity non-invasive ventilation
Description: Single night of high-intensity non-invasive ventilation
Study: NCT04008797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, capsules, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel dosing.
Study: NCT02121678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~* Week 0-4: 70-80 % of 1-RM~* Week 5-8: 75-86 % of 1-RM~* Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~* MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~* CIDP patients train knee (flexion/extension) and elbow (flexion/extension)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data.
Study: NCT01770301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02478346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium
Description: Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
Study: NCT00187915

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil + Tacrolimus
Description: Target MPA exposure to 30-60 mg/L/h during first month post-transplant

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil + Cyclosporin
Description: Target MPA exposure to 30-60 mg/L/h during first month post-transplant
Study: NCT04262765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril, Amlodipine and Atorvastatin
Description: compare the pharmacokinetic of ramipril (and ramiprilat), atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose
Study: NCT04763811

Intervention type: OTHER
Intervention: Focus groups
Description: discussion between participants about representations of health, dependance, fragility, and new technologies

Intervention type: OTHER
Intervention: Individual interviews
Description: Discussion between the searcher and the participant about representations of captors, discretion of captors, wish about feed-backs of captors
Study: NCT03139396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tub shaped inlay bridge design
Description: inlay retained bridge with tub shaped retainer on both abutments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tub shaped inlay bridge design
Description: inlay retained bridge with tub shaped retainer on both abutments
Study: NCT01536041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 200 mg QD, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-6950
Description: 20 mg QD, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10 mg Montelukast, QD single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
Study: NCT03853460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
Study: NCT01119534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaiacol, eucalyptol, menthol and camphor suppository
Description: 2 times per day
Study: NCT03853460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block catheter
Description: ultrasound guided placement of bilateral quadratus lumborum catheters
Study: NCT03410615

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m2 days 1, 22, 43 concurrently with RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given in concurrent and adjuvant phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given in concurrent and adjuvant phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: ARM CLOSED TO ACCRUAL - 2019
Study: NCT01119534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guaiacol suppository
Description: 2 times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin syrup
Description: 4.19 mL - 4 in 4 hours
Study: NCT04148911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 of every 28-day cycle. Day 15: Atezolizumab may be administered on Days 15-18 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle. Day 8: Nab-paclitaxel may be administered on Days 8-11 of each cycle. Day 15: Nab-paclitaxel may be administered on Days 15-18 of each cycle, on the same day with the atezolizumab infusion.
Study: NCT03302871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation